The Effect of Sprouting of Wheat on Postprandial Glycemic and Satiety Responses of Wheat Bread Products
1 other identifier
interventional
12
1 country
1
Brief Summary
The objective of this study is to investigate the effect of inclusion of 50% sprouted wheat wholemeal in a bread recipe on the postprandial glycemic and satiety responses, as well as on appetite-related sensations and acceptability of the developed products relative to a product made with a similar unsprouted wheat recipe.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Oct 2022
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 31, 2022
CompletedFirst Posted
Study publicly available on registry
September 2, 2022
CompletedStudy Start
First participant enrolled
October 18, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 15, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
May 15, 2023
CompletedDecember 5, 2023
December 1, 2023
5 months
August 31, 2022
December 4, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
Postprandial glycemic response
Capillary blood glucose
2 hours
Secondary Outcomes (1)
Postprandial satiety response
2 hours
Study Arms (3)
Sprouted wholemeal bread
EXPERIMENTALUnsprouted wholemeal bread
ACTIVE COMPARATORWhite bread
PLACEBO COMPARATORInterventions
Bread portions of 50 gram available carbohydrates.
Eligibility Criteria
You may qualify if:
- Healthy adults
- Age 18-40 years
- Normal non-fasting plasma glucose (\<7.9 mmol/L but not below 3.3 mmol/L)
- BMI ranging from 18.5 to 27.9 kg/m2
- Regular consumer of wheat-based bread products (\>1x per week).
You may not qualify if:
- Smoking or regular use of recreational drugs (marijuana, ecstasy, LSD, magic mushrooms etc.)
- Heavy alcohol use (defined as typically \>14 drinks per week or \>4 drinks on one occasion)
- Restrained eater (\>16) as defined by the questionnaire at screening (Appendix E: Three Factor Eating Questionnaire, Stunkard et al.,1985)
- Unusual sleep patterns (Shift-worker, or sleeps 4 hours or less regularly) or irregular breakfast consumption.
- Recent (i.e. \>4 kg in previous 3 months) or intended weight loss or gain
- Food allergies or any life-threatening allergy (food or otherwise)
- Gluten intolerance or sensitivity
- Medications known to affect glucose tolerance (excluding oral contraceptives)
- Presence of disease or drug(s) which influence digestion and absorption of nutrients; including steroids, protease inhibitors or antipsychotics.
- Inability to adhere to Study Protocols
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Human Nutraceutical Research Unit
Guelph, Ontario, N1G 2W1, Canada
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- OTHER
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
August 31, 2022
First Posted
September 2, 2022
Study Start
October 18, 2022
Primary Completion
March 15, 2023
Study Completion
May 15, 2023
Last Updated
December 5, 2023
Record last verified: 2023-12
Data Sharing
- IPD Sharing
- Will not share